4,272 Shares in McKesson Co. (NYSE:MCK) Acquired by Wynn Capital LLC

Wynn Capital LLC bought a new stake in shares of McKesson Co. (NYSE:MCK) in the fourth quarter, HoldingsChannel.com reports. The firm bought 4,272 shares of the company’s stock, valued at approximately $1,978,000. McKesson makes up about 1.6% of Wynn Capital LLC’s holdings, making the stock its 14th biggest holding.

A number of other hedge funds have also added to or reduced their stakes in the stock. Alaska Permanent Fund Corp boosted its holdings in shares of McKesson by 2,418.3% during the 4th quarter. Alaska Permanent Fund Corp now owns 12,264 shares of the company’s stock valued at $5,678,000 after purchasing an additional 11,777 shares during the last quarter. Watershed Asset Management L.L.C. increased its position in shares of McKesson by 9.9% during the fourth quarter. Watershed Asset Management L.L.C. now owns 643 shares of the company’s stock worth $298,000 after acquiring an additional 58 shares during the period. GAMMA Investing LLC purchased a new position in shares of McKesson during the fourth quarter worth approximately $330,000. National Wealth Management Group LLC boosted its stake in shares of McKesson by 18.6% during the fourth quarter. National Wealth Management Group LLC now owns 1,359 shares of the company’s stock valued at $629,000 after purchasing an additional 213 shares in the last quarter. Finally, Larson Financial Group LLC boosted its stake in shares of McKesson by 80.9% during the fourth quarter. Larson Financial Group LLC now owns 351 shares of the company’s stock valued at $163,000 after purchasing an additional 157 shares in the last quarter. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

McKesson Price Performance

MCK traded up $3.55 during midday trading on Wednesday, reaching $535.56. 418,139 shares of the company’s stock were exchanged, compared to its average volume of 687,556. The stock has a market capitalization of $70.38 billion, a PE ratio of 24.10, a P/E/G ratio of 1.43 and a beta of 0.45. McKesson Co. has a 1-year low of $352.34 and a 1-year high of $543.00. The business’s 50-day moving average price is $526.12 and its 200 day moving average price is $488.15.

McKesson (NYSE:MCK) last released its quarterly earnings data on Wednesday, February 7th. The company reported $7.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.05 by $0.69. McKesson had a net margin of 0.99% and a negative return on equity of 262.63%. The company had revenue of $80.90 billion during the quarter, compared to the consensus estimate of $77.93 billion. During the same period in the previous year, the firm earned $6.90 earnings per share. McKesson’s revenue for the quarter was up 14.8% on a year-over-year basis. As a group, analysts expect that McKesson Co. will post 27.59 EPS for the current fiscal year.

McKesson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 1st. Shareholders of record on Monday, June 3rd will be paid a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 0.46%. McKesson’s dividend payout ratio (DPR) is 11.24%.

Insider Activity at McKesson

In other McKesson news, EVP Leann B. Smith sold 186 shares of McKesson stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $496.00, for a total value of $92,256.00. Following the completion of the transaction, the executive vice president now directly owns 1,511 shares in the company, valued at $749,456. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other McKesson news, EVP Leann B. Smith sold 186 shares of the company’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $496.00, for a total value of $92,256.00. Following the transaction, the executive vice president now owns 1,511 shares of the company’s stock, valued at $749,456. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Brian S. Tyler sold 3,473 shares of the business’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $524.55, for a total transaction of $1,821,762.15. Following the sale, the chief executive officer now directly owns 43,445 shares in the company, valued at $22,789,074.75. The disclosure for this sale can be found here. 0.21% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Citigroup raised their target price on shares of McKesson from $530.00 to $575.00 and gave the company a “buy” rating in a research note on Thursday, February 8th. Barclays initiated coverage on shares of McKesson in a report on Wednesday, January 3rd. They set an “overweight” rating and a $537.00 target price for the company. Leerink Partnrs reaffirmed an “outperform” rating on shares of McKesson in a report on Monday, February 26th. Mizuho lifted their target price on shares of McKesson from $450.00 to $505.00 and gave the company a “neutral” rating in a research report on Friday, February 9th. Finally, Morgan Stanley lifted their target price on shares of McKesson from $522.00 to $548.00 and gave the company an “overweight” rating in a research report on Monday, April 15th. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, McKesson has a consensus rating of “Moderate Buy” and an average target price of $533.50.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.